CAM 17.1 - A new diagnostic marker in pancreatic cancer

British Journal of Cancer

Volumn 74, Issue 12, 1996, Pages 1997-2002

  Gansauge, F ^a   Gansauge, S ^a   Parker, N ^b   Beger, M I ^a   Poch, B ^a   Link, K H ^a   Safi, F ^a   Beger, Hans G ^a  

^a UNIVERSITY OF ULM   (Germany)

^b DPC   (United Kingdom)

Author keywords

Cell lines; Pancreas; Tumour marker

Indexed keywords

CA 19-9 ANTIGEN; CAM 17.1; MONOCLONAL ANTIBODY; MUCIN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CHRONIC PANCREATITIS; CLINICAL ARTICLE; COLON; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATOBILIARY SYSTEM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA; MALE; PANCREAS CANCER; PANCREAS CARCINOMA; PANCREAS CELL; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SMALL INTESTINE;

EID: 0030457608     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.666     Document Type: Article

References (34)

1. BALAGUE C, GAMBUS G, CARRATO C, PROCHET N, AUBERT JP, KIM YS AND REAL FX. (1994). Altered expression of MUC2, MUC4 and MUC5 mucin genes in pancreas tissue and cancer cell lines. Gastroenterology, 106, 1054-1061.
2. CHING CK AND RHODES JM. (1988). Identification and partial characterization of a new pancreatic cancer-related serum glycoprotein by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and lectin blotting. Gastroenterology, 95, 137-142.
3. CHING CK AND RHODES JM. (1990). Purification and characterization of a peanut-agglutinin-binding pancreatic-cancer-related serum mucus glycoprotein. Int. J. Cancer, 45, 1022-1027.
4. FREBOURG T, BERCOFF E AND MANCHON N. (1988). The evaluation of CA 19-9 antigen level in the early detection of pancreatic cancer. A prospective study of 866 patients. Cancer, 62, 2287-2290.
5. FREISS H, BÜCHLER M, AUERBACH B, WEBER A, MALFERTHEINER P, HAMMER K, MADRY N, GREINER S, BOSSLET K AND BEGER HG. (1993). Ca 494 a new tumour marker for the diagnosis of pancreatic cancer. Int. J. Cancer, 53, 759-763.
6. GANSAUGE S, LINK KH, HUMMEL M, KINDLER D AND BEGER HG. (1994). Establishment and in vitro toxicity studies of two new pancreatic carcinoma cell lines PMH2/89 and PMH3/89. J. Cancer Res. Clin. Oncol., 120, 44.
7. GELDER FB, REESE CJ, MOOSSA AR, HALL T AND HUNTER R. (1978). Purification, partial characterization and clinical evaluation of a pancreatic oncofetal antigen. Cancer Res., 38, 313-324.
8. HABIB N, HERSHAN MJ, HABERLAND F, PAPP L, WOOD CB AND WILLIAMSON RCB. (1986). The use of CA50 radioimmunoassay in differentiating benign and malignant pancreatic disease. Br. J. Cancer, 53, 697-699.
9. HAGLUND C, ROBERTS PJ, KUUSELA P, SCHEININ TM, MÄKELÄ O AND JALANKO H. (1986). Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer. Br. J. Cancer, 53, 197-202.
10. KALINER MA. (1991). Human nasal respiratory secretions and host defense. Am. Rev. Respir. Dis., 144, S52-S56.
11. KALSER MH, BARKIN JS, REDLHAMMER RN AND HEAL A. (1978). Circulating carcinoembryonic antigen in pancreatic carcinoma. Cancer, 42, 1468-1471.
12. KIM YS, GUM JR, BYRD JC AND TORIBARA NW. (1991). The structure of human intestinal apomucins. Am. Rev. Respir. Dis., 144, S10-S14.
13. LUCAROTTI ME, HABIB NA, KELLY SB, ROTHNIE ND, NELSON O AND LINDHOLM L. (1991). Clinical evaluation of combined use of CEA, CA 19-9 and CA50 in the serum of patients with pancreatic carcinoma. Eur. J. Surg. Oncol., 17, 51-53.
14. MAGNANI JL, STEPLEWSKI Z, MITCHELL K, HERLYN M AND KUHNER P. (1983). Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res., 43, 5489-5492.
15. MAKIN CA, BOBROW LG AND BODMER WE. (1984). Monoclonal antibody to cytokeratin for use in routine histopathology. J Clin. Pathol., 37, 975-983.
16. NEUTRA MR AND FORSTNER JF. (1987). Gastrointestinal mucus: synthesis, secretion and function. In Physiology in the Gastrointestinal Tract, Johnson LR, (ed.) pp. 975-1009. Raven Press: New York.
17. NILSSON O, JOHANSSON C, GLIMELIUS B, PERSSON B, NORGAARD-PEDERSEN B AND ANDREN-SANDBERG A. (1992). Sensitivity and specificity of CA242 in gastrointestinal cancer. A comparison with CEA, CA50 and CA 19-9. Br. J. Cancer, 65, 215-221.
18. NORTHOVER J. (1986). Carcinoembryonic antigen and recurrent colorectal cancer. Gut, 27, 117-122.
19. O'DWYER PJ, MOJZISIK C, MCCARBE DP, FARRAR WB, CAREY LC AND MARTIN EW. (1988). Reoperation directed by carcinoembryonic antigen: the importance of a thorough preoperative evaluation. Am. J. Surg., 155, 227-231.
20. OHSHIO G, MANABE T, WATANABE Y, ENDO K, KUDO H, SUZUKI T AND TOBE T. (1990). Comparative studies of DU-PAN-2, Carcinoembryonic antigen, and CA 19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. Am. J. Gastroenterol., 85, 1370-1376.
21. PARKER N, MAKIN CA, CHING CK, ECCLESTON D, TAYLOR OM, MILTON JD AND RHODES JM. (1992). A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/WGA) assessed in combination with CA19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer. Cancer, 70, 1062-1068.
22. PODOLSKY DK, MCPHEE MS, ALPERT E, WARSHAW AL AND ISSELBACHER KJ. (1981). Galactosyltransferase isoenzyme II in the detection of pancreatic cancer: comparison with radiologic, endoscopic and serologic tests. N. Engl. J. Med., 304, 1313-1317.
23. RAOUF A, PARKER N, IDDON D, RYDER S, LANGDON-BROWN B AND MILTON JD. (1991). Ion-exchange chromatography of purified colonic mucus glycoproteins in inflammatory bowel disease: absence of a selective subclass defect. Gut, 32, 1139-1146.
24. ROBERTS PF AND BURNS J. (1972). A histochemical study of mucins in normal and neoplastic human pancreatic tissue. J. Pathol., 187, 87-94.
25. ROSEN VON A, LINDER S, HARMENBURG U AND PEGERT S. (1993). Serum levels of CA 19-9 and CA 50 in relation of lewis blood cell status in patients with malignant and benign pancreatic disease. Pancreas, 8, 160-165.
26. RUSSO AJ, DOUGLASS HO, LEVESON SH, HOWELL JH, HOLYOKE ED, HARVEY SR, CHU TM AND GOLDROSEN MH. (1978). Evaluation of microleukocyte adherence inhibition assay as an immunodiagnostic test for pancreatic cancer. Cancer Res., 38, 2023-2039.
27. SAFI F, BEGER HG, BITTNER R, BÜCHLER M AND KRAUTZBERGER W. (1986). CA19-9 and pancreatic adenocarcinoma. Cancer, 57, 779-783.
28. SCHÜSSLER MH, PINTADO S, WELT S, REAL FX, XU M, MELAMED MR, LLOYD KO AND OETTGEN HF. (1991). Blood group and blood-group-related antigens in normal pancreas and pancreas cancer: enhanced expression of precursor type 1, Tn and sialyl-Tn in pancreas cancer. Int. J Cancer, 47, 180-187.
29. TAKAHASHI HK, METOKI R AND HAKOMORI S. (1988). Immunoglobulin G3 monoclonal antibody directed to Tn antigen (tumor-associated a-N-acetylgalactosaminyl epitope) that does not cross-react with blood-group-A antigen. Cancer Res., 48, 4361-4367.
30. TOSHKOV I, MOGAKI M, KAZAKOFF K AND POUR PM. (1994). The patterns of coexpression of tumour-associated antigens CA 19-9, TAG-72, and DU-PAN-2 in human pancreatic cancer. Int. J. Pancreatol., 15, 97-103.
31. WARSHAW AL, LEE KH, WOOD WC AND COHEN AM. (1980). Sensitivity and specificity of serum ribonuclease in the diagnosis of pancreatic cancer. Am. J. Surg., 139, 27-32.
32. WARSHAW A AND FERNANDEZ-DEL C. (1992). Pancreatic carcinoma. N. Engl. J. Med., 326, 455-465.
33. WESLEY A, MANTLE M, MAN D, QURESHI R, FORSTNER G AND FORSTNER J. (1985). Neutral and acidic species of human intestinal mucin. Evidence for different core peptides. J. Biol. Chem., 260, 7955-7959.
34. XU M, REAL FX, WELT S, SCHÜSSLER MH, OETTGEN HF AND OLD LJ. (1989). Expression of TAG 72 in normal colon, transitional mucose, and colon cancer. Int. J. Cancer, 44, 985-989.